Brain cancer breakthrough? new immunotherapy combo targets recurrent glioblastoma
NCT ID NCT06455605
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a combination of two immunotherapy drugs, D2C7-IT and 2141-V11, for people with recurrent glioblastoma, a fast-growing brain cancer. The treatment is delivered directly into the brain after surgery, followed by injections near the neck to boost the immune response. The goal is to see if this approach is safe and can help control the tumor and extend survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive beads take aim at brain tumours
- Targeted radiation delivered directly to brain tumor cavity in new trial
- Targeted radiation drug shows promise for tough brain tumors
- Engineered immune cells target deadly brain tumors in new trial
- Radioactive antibody and immunotherapy combo targets recurrent brain cancer
- New brain cancer wafer shows promise in recurrent glioblastoma trial